Lynx1 discloses 4.1% Precision BioSciences (DTIL) stake in Schedule 13G/A

Rhea-AI Filing Summary

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 993,913 shares of Precision BioSciences, Inc. common stock, equal to 4.1% of the class as of the calculation date. They hold shared voting and dispositive power over all reported shares, with no sole authority.

The ownership percentage is based on 24,071,751 shares of common stock outstanding, combining 10,815,000 shares issued in a recent offering with 13,256,751 shares outstanding as of October 29, 2025. The reporting persons certify the position is not held to change or influence control of the company.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

PRECISION BIOSCIENCES INC

(Name of Issuer)

Common Stock, par value $0.000005 per share

(Title of Class of Securities)

74019P207

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Lynx1 Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 993,913.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 993,913.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

993,913.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Weston Nichols

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 993,913.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 993,913.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

993,913.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PRECISION BIOSCIENCES INC
(b)	Address of issuer's principal executive offices: 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund"), with respect to the shares of common stock, par value $0.000005 per share ("Common Stock"), of Precision BioSciences, Inc., a Delaware corporation (the "Company"), directly held by the Lynx1 Fund; and (ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Lynx1 Fund. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Weston Nichols c/o Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051
(c)	Citizenship: Investment Manager - Delaware Mr. Nichols - United States of America
(d)	Title of class of securities: Common Stock, par value $0.000005 per share
(e)	CUSIP No.: 74019P207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 24,071,751 shares of Common Stock outstanding, which is the sum of (i) 10,815,000 shares of Common Stock issued in the offering described in the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the "SEC") on November 12, 2025 and (ii) 13,256,751 shares of Common Stock outstanding as of October 29, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 3, 2025.
(b)	Percent of class: 4.1%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lynx1 Capital Management LP

Signature:	/s/ Weston Nichols
Name/Title:	By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
Date:	02/17/2026

Weston Nichols

Signature:	/s/ Weston Nichols
Name/Title:	Weston Nichols, Individually
Date:	02/17/2026

FAQ

What ownership stake in Precision BioSciences (DTIL) does Lynx1 report?

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 993,913 Precision BioSciences shares, representing 4.1% of the outstanding common stock. This reflects a significant but sub‑5% institutional position in the company’s equity.

How is the 4.1% Precision BioSciences (DTIL) ownership percentage calculated?

The 4.1% figure is based on 24,071,751 Precision BioSciences common shares outstanding. This total combines 10,815,000 shares issued in an offering and 13,256,751 shares outstanding as of October 29, 2025, as disclosed in company filings.

Who are the reporting persons in this Precision BioSciences (DTIL) Schedule 13G/A?

The filing identifies Lynx1 Capital Management LP, a Delaware investment manager, and Weston Nichols, its control person, as reporting persons. They report beneficial ownership of the same 993,913 Precision BioSciences common shares through the Lynx1 Master Fund LP.

What voting and dispositive powers does Lynx1 have over Precision BioSciences (DTIL) shares?

The reporting persons disclose shared voting and shared dispositive power over 993,913 shares of Precision BioSciences common stock. They report zero sole voting power and zero sole dispositive power over the company’s shares in this filing.

Is Lynx1’s Precision BioSciences (DTIL) position intended to influence control of the company?

The certification states the securities were not acquired and are not held to change or influence control of Precision BioSciences. They are not held in connection with any control-related transaction, other than activities tied to a nomination under specified proxy rules.

What type of security in Precision BioSciences (DTIL) does Lynx1 own?

Lynx1 reports ownership of common stock of Precision BioSciences with a par value of $0.000005 per share. The filing specifies the relevant CUSIP number 74019P207 to identify the exact class of securities covered.